Please login to the form below
New Accounts, October, 2006 - Advertising
The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period July to September 2006 inclusive
The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period July to September 2006 inclusive. Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may also be involved with some of the products listed in other ways, or in domestic, overseas or international markets.
To submit an entry for New Accounts, email new_accounts@pmlive.com
To submit an entry for New Accounts, email new_accounts@pmlive.com
|
|
|
|
|
|
AstraZeneca |
Symbicort (multimedia) |
Respiratory |
RFA Advertising & Marketing |
|
British Medical Journal |
Clinical Evidence |
N/A |
The Foundry |
|
Eisai/Janssen-Cilag |
Pariet |
Gastrointestinal |
Dewar Alexander |
|
Kogen |
Diclomax |
Arthritis and pain |
Swordfish Advertising |
|
Janssen-Cilag |
Multimedia project |
Migraine |
RFA Advertising & Marketing |
|
Novartis |
Diovan/CoDiovan |
Cardiovascular |
ICC (Lowe Healthcare WW) |
|
Pfizer Consumer Healthcare UK |
Media activity |
OTC and POM portfolio |
Medical Media Services |
|
ProStrakan |
Rapinyl |
Pain management |
Life |
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
Head of Copy
-
£ competitive
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Why pharma must get smart in its approach to customer engagement
- GSK appoint Tony Wood as chief scientific officer
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
- Lucid Group Welcomes a New Cohort of Graduates into its Futures Academy
- Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19
- SMC approves Parkinson’s disease treatment Ongentys
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- Home or away: where next for pharmaceutical symposia?
- PM announces plans to lift England’s COVID-19 restrictions
- Why pharma must get smart in its approach to customer engagement
- AstraZeneca's Enhertu receives FDA grant for priority review
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE
- Amgen’s Lumykras receives conditional marketing authorisation from EC
- SMC approves Parkinson’s disease treatment Ongentys
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
- Cervical Cancer Prevention Month
- In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
- 6 critical success factors for flawless execution of a rapid first commercial launch
- Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
